Core Viewpoint - China Tongfu (01763) has achieved domestic large-scale production of the radioactive nuclide Gallium-68 (Ge-68) using a 30MeV proton cyclotron, meeting commercial product standards in Europe and the US, marking a significant advancement in the country's nuclear medicine capabilities [1] Group 1: Company Developments - The successful production of Ge-68 signifies that China now possesses the ability for stable and independent large-scale manufacturing of this critical nuclide, which is essential for the production of Gallium-68 used in PET imaging for tumor diagnosis [1] - Atom High-Tech will continue to focus on the nuclear medicine sector, increasing investment in the research and development of nuclide drugs and technological innovation to support the development of precision medicine [1] Group 2: Industry Implications - Ge-68 is the parent nuclide of Gallium-68, which decays to produce Gallium-68, a key component in radiopharmaceuticals for tumor imaging, providing crucial diagnostic information for cancer treatment [1] - There are currently 13 Gallium-68 drugs in clinical trials in China, with several already approved for use in cancer diagnosis abroad, indicating a broad market potential for Ge-68 in both domestic and international markets [1]
中国同辐(01763)：原子高科首次实现放射性核素锗-68的国产规模化制备